Haleon buys US shelf space and GLP-1 tie-ins to lift growth
US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.
This is the main new force behind Haleon's US growth push and share gains.
GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.
It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.
First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.
It captures the core tension: solid earnings versus sluggish underlying sales growth.
Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.
It is a new capital action that affects Haleon's cash position and debt profile.